From norbornane-based nucleotide analogs locked in South conformation to novel inhibitors of feline herpes virus

Bioorganic and Medicinal Chemistry

Volumn 22, Issue 11, 2014, Pages 2974-2983

  Dejmek, Milan ^a   Hřebabecký, Hubert ^a   Šála, Michal ^a   Dračínský, Martin ^a   Procházková, Eliška ^a   Leyssen, Pieter ^b   Neyts, Johan ^b   Balzarini, Jan ^b   Nencka, Radim ^a  

^a INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY   (Czech Republic)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Carbocyclic nucleosides; Feline herpes virus; Norbornane; Nucleoside phosphonates; Purine

Indexed keywords

1 [3 HYDROXYBICYCLO[2.2.1]HEPT 1 YL] 5 METHYLPYRIMIDINE 2,4(1H,3H) DIONE; 2 AMINO 9 [3 HYDROXYBICYCLO[2.2.1]HEPT 1 YL] 1,9 DIHYDRO 6 H PURIN 6 ONE; 2 AMINO 9 [3 HYDROXYBICYCLO[2.2.1]HEPT 1 YL] 1,9 DIHYDRO 6H PURIN 6 ONE; 2 AMINO 9 [3 OXOBICYCLO[2.2.1]HEPT 1 YL] 1,9 DIHYDRO 6H PURIN 6 ONE; 4 (2 AMINO 6 CHLORO 9H PURIN 9 YL)BICYCLO[2.2.1]HEPTAN 2 OL; 4 (2 AMINO 6 CHLORO 9H PURIN 9 YL)BICYCLO[2.2.1]HEPTAN 2 ONE; 4 (2,6 DIAMINO 9H PURIN 9 YL)BICYCLO[2.2.1] HEPTAN 2 OL; 4 (6 AMINO 9H PURIN 9 YL)BICYCLO[2.2.1]HEPTAN 2 OL; 4 (6 AMINO 9H PURIN 9 YL)BICYCLO[2.2.1]HEPTAN 2 ONE; 4 (6 CHLORO 9H PURIN 9 YL)BICYCLO[2.2.1]HEPTAN 2 OL; 4 (6 CHLORO 9H PURIN 9 YL)BICYCLO[2.2.1]HEPTAN 2 ONE; 4 (6 SULFANYL 9H PURIN 9 YL)BICYCLO[2.2.1]HEPTAN 2 OL; 4 (6 SULFANYL 9H PURIN 9 YL)BICYCLO[2.2.1]HEPTAN 2 ONE; 4 AMINOBICYCLO[2.2.1]HEPTAN 2 OL HYDROCHLORIDE; 4 [2 AMINO 6 (CYCLOPROPYLAMINO) 9H PURIN 9 YL]BICYCLO[2.2.1]HEPTAN 2 OL; 4 [6 (CYCLOPROPYLAMINO) 9H PURIN 9 YL]BICYCLO [2.2.1]HEPTAN 2 OL; 4 [6 (CYCLOPROPYLAMINO) 9H PURIN 9YL]BICYCLO[2.2.1] HEPTAN 2 ONE; 4 [6 (DIMETHYLAMINO) 9H PURIN 9 YL]BICYCLO[2.2.1] HEPTAN 2 OL; 4 [6 (DIMETHYLAMINO) 9H PURIN 9YL]BICYCLO[2.2.1] HEPTAN 2 ONE; DIISOPROPYL [[[4 (6 AMINO 9H PURIN 9 YL)BICYCLO[2.2.1]HEPT 2 YL]OXY]METHYL]PHOSPHONATE; DIISOPROPYL [[[4 [(TERT BUTOXYCARBONYL)AMINO]BICYCLO[2.2.1]HEPT 2 YL]OXY]METHYL]PHOSPHONATE; DIISOPROPYL [[[4 [2 AMINO 6 (CYCLOPROPYLAMINO) 9H PURIN 9 YL]BICYCLO[2.2.1]HEPT 2 YL]OXY]METHYL] PHOSPHONATE; DIISOPROPYL [[[4 [6 (CYCLOPROPYLAMINO) 9H PURIN 9 YL]BICYCLO[2.2.1]HEPT 2 YL]OXY]METHYL]PHOSPHONATE; GANCICLOVIR; NORBORNANE DERIVATIVE; NUCLEOTIDE DERIVATIVE; TERT BUTYL [3 HYDROXYBICYCLO[2.2.1]HEPT 1 YL]CARBAMATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; [[5 METHYL 2,6 DIOXO 3 [3 (PHOSPHONOMETHOXY)BICYCLO[2.2.1]HEPT 1 YL] 3,6 DIHYDROPYRIMIDIN 1 (2H) YL]METHYL]PHOSPHONIC ACID; ANTIVIRUS AGENT; NUCLEOTIDE;

ALKYLATION; ANTIVIRAL ACTIVITY; ARTICLE; BORDETELLA PERTUSSIS; BROMINATION; CAT; CELL ASSAY; CELL VIABILITY; COXSACKIE VIRUS B3; COXSACKIE VIRUS B4; CURTIUS REARRANGEMENT; DRUG ACTIVITY; DRUG CONFORMATION; DRUG STRUCTURE; DRUG SYNTHESIS; EMBRYO; HERPES VIRUS; HUMAN; HUMAN CELL; KIDNEY CELL CULTURE; NONHUMAN; OXIDATION REDUCTION REACTION; VARICELLA ZOSTER VIRUS; VIRUS INHIBITION; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; FELINE CALICIVIRUS; MICROBIAL SENSITIVITY TEST; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TUMOR CELL LINE;

COXSACKIEVIRUS; FELIDAE; HERPESVIRIDAE;

ANTIVIRAL AGENTS; CALICIVIRUS, FELINE; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; NORBORNANES; NUCLEOTIDES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84899938960     PISSN: 09680896     EISSN: 14643391     Source Type: Journal    
DOI: 10.1016/j.bmc.2014.04.004     Document Type: Article

References (19)

1. T. Cihlar, and A.S. Ray Antiviral Res. 85 2010 39
2. C.G. Boojamra, R.L. Mackman, D.Y. Markevitch, V. Prasad, A.S. Ray, J. Douglas, D. Grant, C.U. Kim, and T. Cihlar Bioorg. Med. Chem. Lett. 18 2008 1120
3. R.L. Mackman, K.Y. Lin, C.G. Boojamra, H. Hui, J. Douglas, D. Grant, O. Petrakovsky, V. Prasad, A.S. Ray, and T. Cihlar Bioorg. Med. Chem. Lett. 18 2008 1116
4. T.F. Wu, M. Froeyen, V. Kempeneers, C. Pannecouque, J. Wang, R. Busson, E. De Clercq, and P. Herdewijn J. Am. Chem. Soc. 127 2005 5056
5. H. Saneyoshi, J.R. Deschamps, and V.E. Marquez J. Org. Chem. 75 2010 7659
6. Boojamara, C. G.; Cannizzaro, C. E.; Chen, J. M.; Chen, X.; Cho, A.; Chong, L. S.; Fardis, M.; Jin, H.; Hirschmann, R. F.; Huang, A. X.; Kim, C. U.; Kirschberg, T. A.; Lee, C. P.; Lee, W. A.; Mackman, R. L.; Markevitch, D. Y.; Oare, D.; Prasad, V. K.; Pyun, H.-J.; Ray, A. S.; Sherlock, R.; Swaminathan, S.; Watkins, W.; Zhang, J. R.; WO2004096286A2.
7. M. Šála, H. Hřebabecký, M. Dračínský, M. Masojídková, A.M. De Palma, J. Neyts, and A. Holý Tetrahedron 65 2009 9291
8. M. Šála, A.M. De Palma, H. Hřebabecký, M. Dejmek, M. Dračínský, P. Leyssen, J. Neyts, H. Mertlíková-Kaiserová, and R. Nencka Bioorg. Med. Chem. Lett. 21 2011 4271
9. M. Šála, H. Hřebabecký, P. Leyssen, M. Dejmek, M. Dračínský, A.M. De Palma, J. Neyts, and R. Nencka Bioorg. Med. Chem. Lett. 22 2012 1963
10. C.I. Tǎnase, C. Drǎghici, M.T. Cǎproiu, S. Shova, C. Mathe, F.G. Cocu, C. Enache, and M. Maganu Bioorg. Med. Chem. 22 2014 513
11. V.E. Marquez, T. Ben-Kasus, J.J. Barchi, K.M. Green, M.C. Nicklaus, and R. Agbaria J. Am. Chem. Soc. 126 2004 543
12. V.E. Marquez, S.H. Hughes, S. Sei, and R. Agbaria Antiviral Res. 71 2006 268
13. H.J. Field, S. Biswas, and I.T. Mohammad Antiviral Res. 71 2006 127
14. E. Thiry, D. Addie, S. Belak, C. Boucraut-Baralon, H. Egberink, T. Frymus, T. Gruffydd-Jones, K. Hartmann, M.J. Hosie, A. Lloret, H. Lutz, F. Marsilio, M.G. Pennisi, A.D. Radford, U. Truyen, and M.C. Horzinek J. Feline Med. Surg. 11 2009 547
15. M. Dejmek, H. Hřebabecký, M. Šála, M. Dračínský, and R. Nencka Synthesis-Stuttgart 2011 4077
16. W.R. Boehme J. Am. Chem. Soc. 81 1959 2762
17. H. Kwart, and G. Null J. Am. Chem. Soc. 81 1959 2765
18. M. Dejmek, S. Kovačková, E. Zborníková, H. Hřebabecký, M. Šála, M. Dračí nský, and R. Nencka RSC Adv. 2 2012 6970
19. L. Čechová, P. Jansa, M. Šála, M. Dračínský, A. Holý, and Z. Janeba Tetrahedron 67 2011 866